Recent Updates
Recently added Catalysts

NNC0471-0119 A

Phase 1

Diabetes Mellitus, Type 1 | Small molecule | Metabolic |Novo Nordisk A/S|Last Updated: Oct 12, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment19
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05262595A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin PumpPHASE1 COMPLETED 19Mar 3, 2022Sep 5, 2022Oct 12, 20231 Austria
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
AUC (NNC0471-0119,0-30min,basal-corrected)/AUC (NNC0471-0119,0-t,basal-corrected)
0 to 12 hours after bolus infusion

Ratio of the basal-corrected area under the serum NNC0471-0119 concentration time curve from 0 to 30 minutes and 0 to t, where t is the first time the curve is back to basal level after bolus infusion (at most 12 hours). Measured in percentage

Secondary Endpoints
AUC (NNC0471-0119,0-t,basal-corrected)
0 to 12 hours after bolus infusion
AUC (NNC0471-0119,0-30min,basal-corrected)
0 to 30 minutes after bolus infusion
AUC (NNC0471-0119,2h-t,basal-corrected)
2 to 12 hours after bolus infusion
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm 1EXPERIMENTALA single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
Arm 2EXPERIMENTALA single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
Arm 3EXPERIMENTALA single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
Arm 4ACTIVE_COMPARATORA single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
Interventions
NameTypeDescription
NNC0471-0119 ADRUGNNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate. The study will last 1-4 months
NNC0471-0119 BDRUGNNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate. The study will last 1-4 months
NNC0471-0119 DDRUGNNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate. The study will last 1-4 months
Faster aspartDRUGFaster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate. The study will last 1-4 months
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 24 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Male participant or female participant of non-childbearing potential. Non-childbearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months...

Countries:Austria
Unlock Eligibility Criteria